SKL 27969
Alternative Names: SKL-27969Latest Information Update: 09 Apr 2024
At a glance
- Originator SK Life Science
- Class Antineoplastics
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 02 Apr 2024 SK Life Science terminates a phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) based on portfolio prioritization (NCT05388435)
- 17 May 2023 9389429 - No update, Trial verified
- 14 Apr 2023 Pharmacodynamics data from preclinical trials in Solid tumours, including Glioblastoma, Non-small cell lung cancer, and Triple negative breast cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)